Showing results (71-80 of 154) with videos related to
Sort By:
Pageof 16
American Journal of Nephrology|March 23, 2021
Predictors of Survival in Chronic Hemodialysis Patients: A 10-Year Longitudinal Follow-Up AnalysisTakuhiro Moromizato, Kentaro Kohagura, Kiyoyuki Tokuyama, et al.Journal of Clinical Medicine|January 8, 2020
Dissimilar Effects of Anagliptin and Sitagliptin on Lipoprotein Subclass in Standard or Strong Statin-Treated Patients with Type-2 Diabetes Mellitus: A Subanalysis of the REASON (Randomized Evaluation of Anagliptin versus Sitagliptin on Low-Density LipoproteiN Cholesterol in Diabetes) TrialHiroyuki Hirai, Moritake Higa, Takeshi Morimoto, et al.Hypertension Research : Official Journal of the Japanese Society of Hypertension|November 18, 2011
Optimal Combination of Effective ANtihypertensives (OCEAN) study: a prospective, randomized, open-label, blinded endpoint trial--rationale, design and results of a pilot study in JapanShigeru Kageyama, Shinichiro Ueda, Kouichi Mochizuki, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 29, 2013
Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trialKunitoshi Iseki, Hisatomi Arima, Kentaro Kohagura, et al.Cardiovascular Diabetology|November 18, 2019
Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trialAtsuko Chihara, Atsushi Tanaka, Takeshi Morimoto, et al.Endocrinology|October 7, 2006
Vascular lipotoxicity: endothelial dysfunction via fatty-acid-induced reactive oxygen species overproduction in obese Zucker diabetic fatty ratsIchiro Chinen, Michio Shimabukuro, Ken Yamakawa, et al.BMJ Open|July 18, 2014
A randomised controlled trial for the evaluation of risk for type 2 diabetes in hypertensive patients receiving thiazide diuretics: Diuretics In the Management of Essential hypertension (DIME) studyShinichiro Ueda, Takeshi Morimoto, Shin-Ichi Ando, et al.ESC Heart Failure|July 16, 2021
WBC count predicts heart failure in diabetes and coronary artery disease patients: a retrospective cohort studyAtsuhiko Kawabe, Takanori Yasu, Takeshi Morimoto, et al.Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|December 28, 2020
Effect of Anagliptin versus Sitagliptin on Inflammatory Markers: Sub-Analysis from the REASON TrialHiroki Teragawa, Takeshi Morimoto, Yuichi Fujii, et al.Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|March 10, 2022
Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON TrialHiroki Teragawa, Takeshi Morimoto, Yuichi Fujii, et al.Pageof 16